Class Action Cases

Join the case to recover your losses. Click "Join this Class Action" above.

Attorneys

Biogen Inc.

Join Class Action »

According to the Complaint, the Company made false and misleading statements to the market. Biogen’s larger dataset failed to provide necessary information on aducanumab’s effectiveness. The Company’s EMERGE study also failed to include necessary data on its effectiveness. This failure extended to the Company’s PRIME study of aducanumab. The Company’s submission to the FDA Peripheral and Central Nervous System Drugs Advisory Committee did not support the efficacy of the drug. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Biogen, investors suffered damages.

Press Release

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Biogen Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Los Angeles, November 13, 2020 — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Biogen Inc. (“Biogen” or “the Company”) (NASDAQ: BIIB) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between October 22, 2019 and November 6, 2020, inclusive (the ”Class Period”), are encouraged to contact the firm before January 12, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Biogen’s larger dataset failed to provide necessary information on aducanumab’s effectiveness. The Company’s EMERGE study also failed to include necessary data on its effectiveness. This failure extended to the Company’s PRIME study of aducanumab. The Company’s submission to the FDA Peripheral and Central Nervous System Drugs Advisory Committee did not support the efficacy of the drug. Based on these facts, the Company’s public statements were false and materially misleading throughout the class period. When the market learned the truth about Biogen, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com

Office: 310-301-3335

info@schallfirm.com

Cases

  • Drop files here or
    Accepted file types: xls, xlsx, doc, pdf, jpg, jpeg.
    You may redact your account numbers from your uploaded documents. The Schall Law Firm is committed to protecting the privacy of confidential information. Your documents will be securely held in AWS S3 and will only be used as proof of your transactions in connection with this matter.
  • Purchases
    Date Format: MM slash DD slash YYYY
  • Sales
    Date Format: MM slash DD slash YYYY
  • By submitting your information, you acknowledge that this form does not create an attorney-client relationship between yourself and The Schall Law Firm. Any information you submit will be maintained as confidential. The Schall Law Firm, in its sole discretion, will contact you if it requires further information from you.